Overview

Vidofludimus Calcium for Primary Sclerosing Cholangitis

Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.
Phase:
Phase 2
Details
Lead Sponsor:
Arizona State University
Elizabeth Carey
Collaborators:
Arizona State University
Mayo Clinic
Treatments:
Calcium
Calcium, Dietary